Introduction
============

COPD, a serious global health problem with a high burden on health care resources, is a leading cause of morbidity and mortality worldwide and is predicted to be the third leading cause of death worldwide by the year 2020.[@b1-copd-13-2435]--[@b4-copd-13-2435] Some COPD patients face pulmonary hypertension (PH) and right heart failure. However, the precise mechanism of this disease and the progression of PH among COPD patients are not fully understood.[@b5-copd-13-2435] Studies have shown that smoking is the most important exogenous risk factor, and other risk factors include exposure to environmental and occupational polycyclic aromatic hydrocarbons.[@b6-copd-13-2435],[@b7-copd-13-2435] Nevertheless, only 20% of long-term smokers develop COPD and 30% lifetime nonsmokers also suffer from COPD,[@b8-copd-13-2435],[@b9-copd-13-2435] which suggests that genetic background plays an important role in development of COPD. Moreover, the differences in clinical presentation and severity of the disease between racial and ethnic groups indicate a significant genetic predisposition to the disease.[@b10-copd-13-2435] Thus, different polymorphisms in potential candidate genes for the development or course of COPD have been detected. α1-Antitrypsin deficiency, the only genetic factor identified so far in predisposing individuals to COPD, affects only minority number of patients, and hence it suggests the existence of a polygenic fixed susceptibility.[@b11-copd-13-2435]

The development of COPD and PH in COPD patients is associated with the activation of the renin--angiotensin--aldosterone system (RAAS), which influences pulmonary vasoconstriction and pulmonary vascular remodeling.[@b5-copd-13-2435],[@b7-copd-13-2435],[@b12-copd-13-2435] Angiotensin-converting enzyme (ACE), a zinc metallo-peptidase highly expressed in the lungs and degrading bradykinin, catalyzes the formation of the Angiotensin II[@b11-copd-13-2435] and plays an important role in RAAS. It is a powerful vasoconstrictor, inflammatory modulator, and cellular growth factor.[@b13-copd-13-2435] Thus, the *ACE* gene has been considered as a contributor to the development of COPD and PH in COPD patients.[@b5-copd-13-2435]

The *ACE* gene is located in chromosome 17q23, and it contains a polymorphism based on the presence (insertion \[I\]) or absence (deletion \[D\]) of a 287-bp nonsense domain in intron 16, resulting in three different genotypes (II, ID, and DD).[@b5-copd-13-2435],[@b7-copd-13-2435] The *ACE* DD genotype is associated with higher circulating and tissue ACE concentration and, therefore, increased activity.[@b13-copd-13-2435] Lower ACE activity is likely to be beneficial to patients in the long-term course of COPD.[@b14-copd-13-2435] A previous study has indicated that the DD genotype is increased in patients with acute adult respiratory distress syndrome (ARDS) and is associated with a higher mortality in the ARDS group.[@b7-copd-13-2435] D-allele carrier status or DD genotype is associated with smokers and their increased risk of developing COPD.[@b11-copd-13-2435] On the contrary, the *ACE* I allele may be associated with a stable course of COPD with less hospital admissions.[@b7-copd-13-2435] However, some studies have reported apparently conflicting results,[@b15-copd-13-2435]--[@b17-copd-13-2435] and because of the small sample size of each study, they possibly lacked sufficient power to assess the true value. So far, whether the *ACE* gene polymorphism is associated with the risk of COPD and COPD with PH has not been systematically assessed.

In the study, we performed a meta-analysis to accurately evaluate the effect of *ACE* gene polymorphism on susceptibility to COPD and COPD with PH. To our knowledge, this is the most recent and comprehensive meta-analysis to assess the relationship to date.

Methods
=======

Literature search
-----------------

We performed a literature search in PubMed, Embase, Wanfang Database, and China National Knowledge Infrastructure (CNKI), covering all studies published up to 17 March 2018, using the search keywords "angiotensin-converting enzyme, ACE, polymorphism, chronic obstructive pulmonary disease, COPD, pulmonary hypertension, PH", as well as combinations of these terms. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications. The studies published in English or Chinese were included. Additionally, we also conducted a web-based search using a variety of commercial Internet search engines (such as Google and Baidu), using the same technique. Only published studies with full-text articles were included. If studies had partially overlapped samples, only the most recent or complete study was selected.

Study selection
---------------

We included studies that met the following criteria: (a) published in English or in Chinese and (b) with a case--control study design, (c) that supply the available genotype frequencies in cases and controls and (d) with available data for calculating odds ratio (OR) and 95% CI provided in the primary study, and (e) that involved human subjects as the main object of study. Studies were excluded if they come under the following criteria: (a) lacking a control cohort, (b) being a review and overlapping study, and (c) not showing the available data or other essential information.

Quality-score evaluation
------------------------

The quality of the included studies was assessed according to the Newcastle--Ottawa scale (case--control study). The scale to estimate the quality was based on three aspects, including selection, comparability, and exposure in the primary study. The total scores ranged from 0 to 9 (0--3, 4--6, and 7--9 indicated low, moderate, and high quality, respectively).

Data extraction
---------------

Two of the authors (Yao Ma and Xiang Tong) independently collected detailed information and data from each study using a predesigned data extraction Excel form. If there were a disagreement, the third author (Ying Liu) would estimate these articles. The information and data extracted included first author, publication year, country, ethnicity of study population, case and control group size, age of the participant, genotype and allele distribution, and test method.

Statistical methods
-------------------

In the present study, the OR and 95% CI were used to investigate the strength of the association effect between *ACE* gene polymorphism and COPD susceptibility. The Hardy--Weinberg equilibrium was tested by using the *χ*^2^ test in each control group before performing the meta-analysis. We calculated the heterogeneity by using the *χ*^2^-based *Q*-test and *I*^2^ statistic tests. The pooled effect size (OR) would be assessed by using the random-effect model if the heterogeneity was considered statistically significant (*I*^2^\>50% and *P*\<0.10); if not, the fixed-effect model was used. To evaluate the ethnicity-specific effects, we also performed subgroup analyses considering different specific effects.

In addition, publication bias was assessed using several methods. Visual inspection of asymmetry in funnel plots was carried out, and the Begg's and Egger's tests were used to assess further the publication bias. All data analyses were conducted using the STATA 12.0 software.

Results
=======

Study characteristics
---------------------

Initially, we performed a search in PubMed, Embase, Wanfang Database, and CNKI and identified 66 articles ([Figure 1](#f1-copd-13-2435){ref-type="fig"}). We rejected and removed 35 articles because they were repeated studies. Eight articles were excluded after reading the titles and abstracts. Two articles were excluded because they were not relevant to COPD or/and risk of PH in COPD in relation to the *ACE* gene polymorphism. Two other articles were eliminated because they were reviews. One study was rejected because it was an animal experiment, and another article was not included in the meta-analysis because it was not designed as a case--control study. Finally, we confirmed 15 eligible studies (1,279 cases and 1,356 controls)[@b7-copd-13-2435],[@b10-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b25-copd-13-2435] for the COPD subgroup and four studies for the PH subgroup, and we included them in the current meta-analysis. Twelve articles were in English,[@b7-copd-13-2435],[@b10-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b20-copd-13-2435],[@b23-copd-13-2435],[@b25-copd-13-2435] and three were in Chinese.[@b21-copd-13-2435],[@b22-copd-13-2435],[@b24-copd-13-2435] Among these studies, five were conducted in Asians and ten in Caucasians. Additionally, according to the quality-score evaluation, six articles were of moderate quality, and the others were of high quality. The characteristics of the collected studies are listed in [Tables 1](#t1-copd-13-2435){ref-type="table"} and [2](#t2-copd-13-2435){ref-type="table"}.

Association between ACE gene polymorphism and COPD
--------------------------------------------------

In total, 15 studies (1,279 cases and 1,356 controls) reported the association between *ACE* gene polymorphism and COPD susceptibility. The evaluation of the association between *ACE* gene polymorphism and COPD risk is shown in [Table 3](#t3-copd-13-2435){ref-type="table"}. Overall, the results indicated that there were no significant associations between COPD risk and D allele, compared to that with I allele. In addition, the overall analysis results indicated that the *ACE* gene polymorphism was not associated with COPD susceptibility in all gene models ([Figure 2](#f2-copd-13-2435){ref-type="fig"}). However, we found a significant heterogeneity between studies in the meta-analysis, and we executed a sensitivity analysis by sequentially excluding studies from the meta-analysis to investigate the influence of each study on the pooled results. The results of sensitivity analysis found that the pooled OR was not significantly altered ([Figure 3](#f3-copd-13-2435){ref-type="fig"}). Therefore, we further carried out a subgroup analysis, and the results indicated that DD homozygous genotype was significantly associated with COPD in dominant model (DD+DI vs II, OR=1.47, *P*=0.019, 95% CI: 1.07--2.02; [Figure 4](#f4-copd-13-2435){ref-type="fig"}), recessive model (DD vs DI+II, OR=2.38, *P*=0.003, 95% CI: 1.34--4.22; [Figure 5](#f5-copd-13-2435){ref-type="fig"}), codominant model (DD vs II, OR=2.68, *P*\<0.001, 95% CI: 1.76--4.08; [Figure 6](#f6-copd-13-2435){ref-type="fig"}), and allele model (D vs I, OR=1.62, *P*=0.005, 95% CI: 1.16--2.27; [Figure 7](#f7-copd-13-2435){ref-type="fig"}), but this was not true in Caucasians. Funnel plots were almost symmetrical ([Figure 8](#f8-copd-13-2435){ref-type="fig"}). No publication bias was found in the funnel plot, Begg's test (*P*=0.621), or Egger's test (*P*=0.991).

Association between ACE gene polymorphism and PH
------------------------------------------------

The overall results of the present study detected no statistical significance between the *ACE* gene polymorphism and the risk of PH in COPD patients. Interestingly, we found that the homozygote variant (DD) increased the risk of PH in Asian COPD patients (DD vs ID+II, OR=2.05, *P*=0.05, 95% CI: 1.00--4.19; [Figure 9](#f9-copd-13-2435){ref-type="fig"}).

Discussion
==========

Many previous studies have revealed that the development and progression of COPD are affected by host genetic factors.[@b10-copd-13-2435],[@b16-copd-13-2435],[@b26-copd-13-2435]--[@b29-copd-13-2435] Many researchers have reported the association between *ACE* D allele polymorphism and the susceptibility to COPD and COPD with PH.[@b7-copd-13-2435],[@b11-copd-13-2435],[@b16-copd-13-2435],[@b20-copd-13-2435] Unfortunately, some other results were inconclusive.[@b15-copd-13-2435]--[@b17-copd-13-2435] Thus, we conducted a comprehensive meta-analysis to assess this relationship accurately.

The results of the meta-analysis indicated that the *ACE* gene polymorphism was not associated with susceptibility to COPD in overall gene models. However, we found a significant heterogeneity between studies in the meta-analysis, which may be attributed to many factors, such as different demographic and genetic characteristics of Caucasian and Asian populations and the different quality of the included studies. Although the heterogeneity can be taken into account by conducting the random-effect model, it would increase the odds of type I error. To identify further reasons for the heterogeneity, we carried out a sensitivity analysis by sequentially excluding each study, and statistically similar results were obtained, suggesting the stability of the meta-analyses. Therefore, we performed a subgroup analysis to investigate the effect of ethnicity. Surprisingly, the subgroup analysis results showed that the *ACE* gene polymorphism, especially the DD genotype, increased the risk of susceptibility to COPD in Asians, but not in Caucasians. Nevertheless, the studies on patients with COPD with PH involved in the meta-analysis were mainly carried out in China, as well as the studies were with small sample size. Therefore, the results should be interpreted cautiously and studies with larger sample size should be carried out in future to confirm the conclusion derived from this study.

Compared with I allele, the D allele is associated with higher concentration and activity of circulating and tissue *ACE*,[@b7-copd-13-2435],[@b13-copd-13-2435],[@b30-copd-13-2435] which could have potential effects on pulmonary vascular inflammation, which is the central feature of COPD associated with lung remodeling, parenchymal destruction, and the development of emphysema.[@b7-copd-13-2435],[@b31-copd-13-2435] Peinado et al confirmed the presence of inflammatory changes in the pulmonary capillary bed in patients with mild COPD without hypoxemia.[@b32-copd-13-2435] Tkacova and Joppa found that serum high-sensitivity C-reactive protein increased from the homozygous II to the heterozygous ID and then to the homozygous DD *ACE* genotype group, suggesting that the *ACE* plays an important role in vascular micro-inflammation.[@b33-copd-13-2435] ACE catalyzes the conversion of AngI into AngII, which stimulates the release of cytokines such as monocyte chemotactic protein-1, and the latter has been shown to activate tissue mast cells in response to acute alveolar hypoxia, thereby triggering systemic inflammation.[@b34-copd-13-2435] Wong et al found that the cytokine response mediated by AngII was inhibited by losartan, an AT1 receptor antagonist.[@b35-copd-13-2435] Their findings, which are consistent with our results, can explain why the *ACE* DD genotype increased the risk of COPD.

In addition, as a serious complication, PH develops in 30%--70% of patients with COPD, thereby increasing morbidity and mortality.[@b36-copd-13-2435] The current study showed that the homozygote variant (DD) increased the risk of PH in COPD patients among Asians. The previous studies indicated that the main mechanisms involved in the increase in pulmonary artery pressure include vasoconstriction and pulmonary vascular remodeling.[@b5-copd-13-2435],[@b17-copd-13-2435],[@b36-copd-13-2435] Increased endothelium expression of ACE in small intra-acinar arteries has been shown in primary or secondary PH,[@b31-copd-13-2435] suggesting that increased ACE-induced AngII production contributes to PH. Further, lowering the ACE level reduces PH by controlling vasoconstriction.[@b37-copd-13-2435] A large retrospective study in elderly patients hospitalized for COPD exacerbation identified that the use of ACE inhibitor or angiotensin II receptor blocker, when controlling for demographics, comorbidities, and other medication, was significantly associated with a decreased 90-day mortality following their COPD hospital presentation.[@b38-copd-13-2435] Moreover, a study found that the abovementioned effects were enhanced by the degradation of bradykinin, which mediated the release of the vasodilator nitric oxide and prostaglandins.[@b31-copd-13-2435] Olson et al suggested that the vasodilation effect of ACE inhibitor was improved through maximization of the bioavailability of bradykinin.[@b39-copd-13-2435] As previously mentioned, *ACE* D polymorphism is associated with a higher concentration and activity of circulating and tissue ACE, which increases the predisposition to COPD with PH.

Interestingly, we also found no association of *ACE* gene polymorphism with the risk of susceptibility to COPD or COPD with PH in Caucasians, whereas the D allele or DD genotype increased the risk of susceptibility to COPD and COPD with PH in Asians. Our finding is in accord with the studies of Li et al[@b37-copd-13-2435] and Kanazawa et al,[@b40-copd-13-2435] respectively. Further, the sample size used for meta-analysis in our study is larger than that used in Li et al's study.[@b37-copd-13-2435] Moreover, we performed the subgroup analysis and the sensitivity analysis, and hence, our results are more reliable. Finally, we analyzed the association of *ACE* polymorphism and COPD with PH.

Additionally, there were several reasons that might have contributed to the different results between different ethnicities. First, different genetic backgrounds may account for the different results. Second, the different living environments of Asians and Caucasians may contribute to the different genetic effects. Third, the interaction with other predisposed gene polymorphism in different ethnicities may also be an influencing factor. Therefore, the recognition of a genetic susceptibility to COPD and COPD with PH and identification of the *ACE* polymorphism in the pathogenesis of COPD and COPD with PH could help us to predict the prognosis of COPD and influence our choice of treatment.

COPD is a complex disease which is influenced by the environment, genetic factors, and genotype--environment interactions. Cigarette smoking, ambient air pollution, underweight, infant respiratory infection, childhood chronic cough, parental history of respiratory diseases, low education, and early-life home overcrowding are risk factors for COPD.[@b2-copd-13-2435],[@b6-copd-13-2435] McCloskey et al found that there was a significant familial risk of airflow limitation observed in people who smoked and were siblings of patients with severe COPD, suggesting that genetics together with environmental factors could influence the susceptibility to COPD and PH.[@b41-copd-13-2435] A study shows that the presence of the DD ACE genotype may increase the risk of smokers who are about to develop COPD.[@b11-copd-13-2435] Identification of the specific genes and the specific environmental factors that interact is of great interest in human genetics. For the complex respiratory disease, some environmental factors are important but are difficult to measure and it is not necessary to know the influences of specific gene and environment on a phenotype to determine if a genotype--environment interaction is present.[@b42-copd-13-2435] In addition, because of the lack of original information in the literatures, we could not extract environment-related data. In the future, more rigorous studies in which data will be stratified by other variables, such as smoking, ambient air pollution, age, and gender will be conducted to confirm the results.

Limitations
===========

Some limitations of this meta-analysis should be considered. First, the subjects of the meta-analysis were Asians and Caucasians and there were no Africans recruited, so the conclusion is limited to Asian and Caucasian populations. Second, only studies included in the selected databases were included in our data analysis, and thus some relevant published or unpublished studies might have been missed. Third, because of the lack of original information on individuals, data were not stratified by other variables, such as gene--gene interaction, gene--environment interaction, and patients' gender and age.

Conclusion
==========

The current meta-analysis suggests that *ACE* gene polymorphism might be a risk factor in the pathogenesis of COPD and COPD with PH among Asians. We strongly recommend that in the future, researchers should design more rigorous and uniform case--control or cohort studies and include more ethnicities to confirm the results.
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![Forest plot for the association between ACE and COPD risk in recessive genetic model (DD vs DI+II).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** ACE, angiotensin-converting enzyme; OR, odds ratio.](copd-13-2435Fig5){#f5-copd-13-2435}

![Forest plot for the association between ACE and COPD risk in codominant genetic model (DD vs II).\
**Abbreviations:** ACE, angiotensin-converting enzyme; OR, odds ratio.](copd-13-2435Fig6){#f6-copd-13-2435}

![Forest plot for the association between ACE and COPD risk in allele genetic model (D vs I).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** ACE, angiotensin-converting enzyme; OR, odds ratio.](copd-13-2435Fig7){#f7-copd-13-2435}

![Funnel plot to test publication bias of studies under the dominant model (DD+DI vs II).\
**Abbreviations:** OR, odds ratio; s.e., standard error.](copd-13-2435Fig8){#f8-copd-13-2435}

![Forest plot for the association between ACE and PH risk under recessive genetic model (DD vs DI+II).\
**Abbreviations:** ACE, angiotensin-converting enzyme; PH, pulmonary hypertension; OR, odds ratio.](copd-13-2435Fig9){#f9-copd-13-2435}

###### 

Characteristics of case--control studies included in the meta-analysis

  Study                                 Year   Country    Ethnicity   Cases/controls   Age                       Method     *Q* score
  ------------------------------------- ------ ---------- ----------- ---------------- ------------------------- ---------- -----------
  COPD                                                                                                                      
   Ahsan et al[@b10-copd-13-2435]       2004   India      Asian       27/66            NA                        PCR-RFLP   7
   Ayada et al[@b20-copd-13-2435]       2014   Turkey     Caucasian   47/64            NA                        PCR-RFLP   6
   Busquets et al[@b11-copd-13-2435]    2007   Spain      Caucasian   74/159           62±2/NA                   PCR-RFLP   8
   Gu et al[@b22-copd-13-2435]          2003   China      Asian       122/159          60.8/63.5                 PCR-RFLP   5
   Hopkinson et al[@b13-copd-13-2435]   2004   England    Caucasian   103/101          64.1±9.1/61.8±8.6         PCR-RFLP   7
   Jiang and Zhang[@b24-copd-13-2435]   2002   China      Asian       60/30            34--80/35--78             PCR-RFLP   5
   Kuzubova et al[@b18-copd-13-2435]    2013   Russia     Caucasian   63/95            60.4±1.0/57.3±1.7         PCR-RFLP   8
   Mlak et al[@b25-copd-13-2435]        2016   Poland     Caucasian   206/165          63±9.4/64±10.6            PCR-RFLP   8
   Pabst et al[@b7-copd-13-2435]        2009   Germany    Caucasian   152/158          62.8±11.1/63.9±18.4       PCR-RFLP   7
   Simsek et al[@b19-copd-13-2435]      2013   Turkey     Caucasian   66/40            61.23±11.41/59.17±11.23   PCR-RFLP   7
   Tkácová et al[@b17-copd-13-2435]     2005   Slovakia   Caucasian   66/118           65.4±2.5/63.5±1.2         PCR-RFLP   7
   Ulasli et al[@b16-copd-13-2435]      2013   Turkey     Caucasian   80/49            65.1±7.60/54.6±7.8        PCR-RFLP   6
   Xu[@b21-copd-13-2435]                2002   China      Asian       110/55           69.66±6.60/68.86±11.02    PCR-RFLP   5
   Yildiz et al[@b15-copd-13-2435]      2003   Turkey     Caucasian   42/40            62±7/60±8                 PCR-RFLP   7
   Zhang et al[@b23-copd-13-2435]       2008   China      Asian       61/57            63.8±8.2/61.6±7.3         PCR-RFLP   6
  PH                                                                                                                        
   Jiang and Zhang[@b24-copd-13-2435]   2002   China      Asian       30/30            50--80/35--78             PCR-RFLP   5
   Ulasli et al[@b16-copd-13-2435]      2013   Turkey     Caucasian   30/50            66.9±7.2/54.6±7.8         PCR-RFLP   6
   Xu[@b21-copd-13-2435]                2002   China      Asian       57/53            70.02±8.21/68.86±11.02    PCR-RFLP   5
   Yildiz et al[@b15-copd-13-2435]      2003   Turkey     Caucasian   24/14            62±4.8/60±8               PCR-RFLP   6

**Abbreviations:** PH, pulmonary hypertension; NA, not available; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

###### 

Distributions of ACE allele and genotypes in different studies' susceptibility to COPD

  Study                                 Language   Year   COPD   Control   HWE                                          
  ------------------------------------- ---------- ------ ------ --------- ----- ----- ----- ---- ---- ---- ----- ----- -------
  COPD                                                                                                                  
   Ahsan et al[@b10-copd-13-2435]       English    2004   5      12        10    22    32    10   31   23   51    77    0.93
   Ayada et al[@b20-copd-13-2435]       English    2014   13     26        8     52    42    28   28   8    84    44    0.81
   Busquets et al[@b11-copd-13-2435]    English    2007   27     40        7     94    54    53   79   27   185   133   0.79
   Gu et al[@b22-copd-13-2435]          Chinese    2003   57     37        28    151   93    25   85   49   135   183   0.24
   Hopkinson et al[@b13-copd-13-2435]   English    2004   25     49        29    99    107   24   49   28   97    105   0.78
   Jiang and Zhang[@b24-copd-13-2435]   Chinese    2002   24     20        16    68    52    5    10   15   20    40    0.17
   Kuzubova et al[@b18-copd-13-2435]    English    2013   17     29        17    63    63    22   49   24   93    97    0.75
   Mlak et al[@b25-copd-13-2435]        English    2016   60     99        47    219   199   51   73   41   175   155   0.15
   Pabst et al[@b7-copd-13-2435]        English    2009   33     76        43    142   162   50   69   39   169   147   0.12
   Simsek et al[@b19-copd-13-2435]      English    2013   31     20        15    82    50    13   19   8    45    35    0.83
   Tkácová et al[@b17-copd-13-2435]     English    2005   20     31        15    71    61    31   68   19   130   106   0.07
   Ulasli et al[@b16-copd-13-2435]      English    2013   47     17        16    111   49    33   10   6    76    22    0.003
   Xu[@b21-copd-13-2435]                Chinese    2002   22     56        32    100   120   7    25   23   39    71    0.96
   Yildiz et al[@b15-copd-13-2435]      English    2003   14     21        7     49    35    12   18   10   42    38    0.54
   Zhang et al[@b23-copd-13-2435]       Chinese    2008   13     27        21    53    69    9    28   20   46    68    0.88

                                                         COPD with PH             COPD without PH                                           
  ------------------------------------- --------- ------ -------------- ---- ---- ----------------- ---- ---- ---- ---- ---- ---- ---- ---- ----
  PH                                                                                                                                        
   Jiang and Zhang[@b24-copd-13-2435]   Chinese   2002   13             8         9                 34   26   11   12        7    34   26   NA
   Ulasli et al[@b16-copd-13-2435]      English   2013   19             6         5                 44   16   28   11        11   67   33   NA
   Xu[@b21-copd-13-2435]                Chinese   2002   16             25        16                57   57   6    31        16   43   63   NA
   Yildiz et al[@b15-copd-13-2435]      English   2003   7                   17                     NA   NA   4         10        NA   NA   NA

**Abbreviations:** ACE, angiotensin-converting enzyme; HWE, Hardy--Weinberg equilibrium; PH, pulmonary hypertension; NA, not available.

###### 

Summary of total results and subgroup analysis from different comparative genetic models

  Genetic models   COPD                                                                                                                        COPD+PH                                                                                                                                                              
  ---------------- --------------------------------------------------------------------------------------------------------------------------- --------- ------------ ------- -------- ------ ---------------------------------------------------------------------------------- ------ ------------ ------ ------- ------
  DD+ID vs II                                                                                                                                                                                                                                                                                                       
   Overall         15[@b7-copd-13-2435],[@b10-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b25-copd-13-2435]   1.10      0.90--1.34   0.34    Fixed    17.3   3[@b16-copd-13-2435],[@b21-copd-13-2435],[@b24-copd-13-2435]                       1.05   0.59--1.89   0.86   Fixed   0
   Asians          5[@b10-copd-13-2435],[@b21-copd-13-2435]--[@b24-copd-13-2435]                                                               1.48      1.07--2.03   0.02    Fixed    0      2[@b21-copd-13-2435],[@b24-copd-13-2435]                                           0.95   0.49--1.86   0.89   Fixed   0
   Caucasians      10[@b7-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b20-copd-13-2435],[@b25-copd-13-2435]   0.92      0.71--1.18   0.49    Fixed    0      1[@b16-copd-13-2435]                                                               1.41   0.44--4.55   0.57   Fixed   0
  DD vs DI+II                                                                                                                                                                                                                                                                                                       
   Overall         15[@b7-copd-13-2435],[@b10-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b25-copd-13-2435]   1.27      0.88--1.82   0.21    Random   69.6   4[@b15-copd-13-2435],[@b16-copd-13-2435],[@b21-copd-13-2435],[@b24-copd-13-2435]   1.64   0.97--2.78   0.07   Fixed   0
   Asians          5[@b10-copd-13-2435],[@b21-copd-13-2435]--[@b24-copd-13-2435]                                                               2.36      1.32--4.22   0.004   Random   51.8   2[@b21-copd-13-2435],[@b24-copd-13-2435]                                           2.05   1.00--4.19   0.05   Fixed   21.0
   Caucasians      10[@b7-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b20-copd-13-2435],[@b25-copd-13-2435]   0.93      0.74--1.16   0.52    Fixed    26.6   2[@b15-copd-13-2435],[@b16-copd-13-2435]                                           1.25   0.57--2.74   0.57   Fixed   0
  DD vs II                                                                                                                                                                                                                                                                                                          
   Overall         15[@b7-copd-13-2435],[@b10-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b25-copd-13-2435]   1.28      0.86--1.90   0.22    Random   58.4   3[@b16-copd-13-2435],[@b21-copd-13-2435],[@b24-copd-13-2435]                       1.60   0.80--3.18   0.19   Fixed   0
   Asians          5[@b10-copd-13-2435],[@b21-copd-13-2435]--[@b24-copd-13-2435]                                                               2.68      1.76--4.08   0.000   Fixed    25.9   2[@b21-copd-13-2435],[@b24-copd-13-2435]                                           1.65   0.71--3.83   0.24   Fixed   31.6
   Caucasians      10[@b7-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b20-copd-13-2435],[@b25-copd-13-2435]   0.89      0.66--1.20   0.44    Fixed    5.7    1[@b16-copd-13-2435]                                                               1.49   0.45--4.99   0.52   Fixed   0
  DI vs II                                                                                                                                                                                                                                                                                                          
   Overall         15[@b7-copd-13-2435],[@b10-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b25-copd-13-2435]   0.99      0.80--1.22   0.91    Fixed    0      3[@b16-copd-13-2435],[@b21-copd-13-2435],[@b24-copd-13-2435]                       0.79   0.41--1.50   0.47   Fixed   0
   Asians          5[@b10-copd-13-2435],[@b21-copd-13-2435]--[@b24-copd-13-2435]                                                               1.07      0.75--1.51   0.71    Fixed    0      2[@b21-copd-13-2435],[@b24-copd-13-2435]                                           0.71   0.34--1.46   0.35   Fixed   0
   Caucasians      10[@b7-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b20-copd-13-2435],[@b25-copd-13-2435]   0.94      0.72--1.23   0.66    Fixed    0      1[@b16-copd-13-2435]                                                               1.20   0.28--5.12   0.81   Fixed   0
  D vs I                                                                                                                                                                                                                                                                                                            
   Overall         15[@b7-copd-13-2435],[@b10-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b25-copd-13-2435]   1.14      0.91--1.41   0.25    Random   66.2   3[@b16-copd-13-2435],[@b21-copd-13-2435],[@b24-copd-13-2435]                       1.30   0.90--1.87   0.16   Fixed   0
   Asians          5[@b10-copd-13-2435],[@b21-copd-13-2435]--[@b24-copd-13-2435]                                                               1.63      1.17--2.27   0.004   Random   54.0   2[@b21-copd-13-2435],[@b24-copd-13-2435]                                           1.28   0.83--1.96   0.26   Fixed   0
   Caucasians      10[@b7-copd-13-2435],[@b11-copd-13-2435],[@b13-copd-13-2435],[@b15-copd-13-2435]--[@b20-copd-13-2435],[@b25-copd-13-2435]   0.94      0.81--1.09   0.41    Fixed    18.9   1[@b16-copd-13-2435]                                                               1.35   0.67--2.75   0.40   Fixed   0

**Note:**

Number of case--control studies.

**Abbreviations:** PH, pulmonary hypertension; OR, odds ratio.

[^1]: These authors contributed equally to this work
